Abraxane developer Iglesias joins Senti Biosciences; AB2Bio recruits CEO
→ After accumulating more than 30 years of biopharma experience, Jose Iglesias has been named CMO of Senti Biosciences, a gene circuit company based in the San Francisco area. Iglesias is slated to lead Senti’s clinical development programs with an emphasis on treating solid and liquid tumors. Iglesias designed the cancer drug Abraxane while he was at Abraxis and Celgene, and his extensive background also includes leadership positions at Eli Lilly, Apobiologix and Boston BioMedical.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.